Latest News and Press Releases

FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, April 12, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc...

NEW YORK and LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye. Elevated...

Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets.Votucalis...

NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...

Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European...

New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion...

New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degenerationIn the experimental allergic uveitis (EAU) disease model nomacopan reduced Th17 effector...

Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BPThe Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to...

FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded access programFollowing initial proof of...